Introduction
Major limitations to efficacious immune-therapy are mechanisms of central and peripheral T cell tolerance, which weaken tumor immunogenicity (1) . Several strategies have been attempted to break such tolerance with variable degrees of success in preclinical mouse models, and in clinical trials (2) . Active immunotherapy in the form of vaccines targeted to tumor-associated antigens have led to promising results (3) , and to the recent approval of Sipuleucel-T by the US Food and Drug Administration (FDA). Sipuleucel-T is the first therapeutic vaccine for the therapy of asymptomatic metastatic castrate-resistant prostate cancer, but it's impact on overall patient survival remains modest and is still under debate (4, 5) . Being among the most successful immunotherapeutic strategies, adoptive cell therapies that leverage on tumor-specific T cells expanded in vitro or generated by TCR gene transfer (6) , as well as allogeneic transplantation of hematopoietic stem cells (HSCT) (7) have yielded promising therapeutic responses. The infusion of donor-derived mature T cells (donor lymphocyte infusion; DLI) following HSCT provides further clinical benefit, especially against relapsed hematological malignancies. Therapeutic efficacy is generally due to the allogeneic reaction of donor T cells to host leukemic cells (8) and to transplanted T cells with specificity for host tumor-associated antigens.
Expansion of donor T cells is favored under lymphopenic conditions (9).
To date, active and adoptive immunotherapy and HSCT/DLI approaches are still of limited efficacy against most solid tumors, except for melanoma and renal cancer (10), which is possibly due to rather profound mechanisms of peripheral tolerance and the failure of tumor-reactive T cells to properly infiltrate the tumor (8) .
The combination of HSCT/DLI and tumor-directed vaccination holds the potential to enhance the graft versus tumor (GVT) response, without favoring the graft versus host (GVH) effect (9) . Indeed, post-transplant vaccines have previously been shown to augment the efficacy of HSCT/DLI against hematological cancers (11-15) and in some instances also against transplantable solid tumors (16).
We recently reported that HSCT and DLI from HY mismatched female donors, pre- Whether the combined strategy might be efficacious also in the case of more clinically relevant settings, i.e. in mice transplanted with HSCT/DLI from naïve, nonsensitized donors, mismatched to the recipient for defined sets of multiple minor H antigens remained to be defined. Here we addressed this issue and also investigated the mechanism of action of post-transplant tumor-directed vaccination in TRAMP mice transplanted with HSCT/DLI from naïve donors, mismatched to the TRAMP for either Y chromosome-encoded or multiple minor H antigens. We show that also in the case of non-sensitized donors, HSCT/DLI can be of therapeutic efficacy, initiates
Materials and Methods
Mice, cell lines and reagents. Congenic C57BL/6 CD45.2 (B6.CD45.2), C57BL/6 CD45.1 (B6.CD45.1) and BALB.B mice were obtained from Charles River. CD45.2 + C57BL/6 TRAMP heterozygous mice were genotyped as described (22) Hematopoietic cell transplantation and tumor-directed vaccination. Mice were subjected to non-myeloablative HSCT as previously described (17). Briefly, recipient mice were sub-lethally irradiated (600 rad) and transplanted intravenously (i.v.) with following day. For post-transplant vaccination, bone marrow-derived dendritic cells (DC) were LPS matured, pulsed for 1h at 37°C with 2μM Tag-IV peptide (VVYDFLKC) and injected subcutaneously (s.c.) (4×10 5 DC/mouse), as previously described (22). Mice were vaccinated one day after DLI, boosted three weeks later and sacrificed after an additional week, or boosted once a month for survival studies.
Mice with an early onset of highly aggressive, poorly differentiated neuroendocrine tumors were excluded from the survival analysis (generally observed in 10-15% of mice). In selected experiments, LPS-matured DC were simultaneously pulsed with the class I Tag-IV peptide and the class II Tag362-384 peptide (both at 2μM). Mice were vaccinated one day after DLI, boosted three weeks later and sacrificed after an additional week for disease scoring.
Flow cytometry, histology and immunohistochemistry. Single cell suspensions of spleen and peripheral lymph nodes were either stained with the appropriate fluorochrome-labeled monoclonal antibodies ex vivo, or re-stimulated in vitro with 2μM Tag-IV, Uty (WMHHNMDLI) or Dby (NAGFNSNRANSSRSS) peptide and were subsequently incubated for 4 hours, of which the last two were in the presence of brefeldin A. Thereafter, cells were surface stained, fixed and permeabilized, and intracellular cytokine measurement was performed as previously described (17).
The urogenital apparatus (UGA) was embedded in Paraffin and processed for histology and immunohistochemistry. Coded slides of UGA sections stained by H&E were scored by a pathologist as previously described (17). Briefly, a score of 0 was given to prostates showing complete tumor regression (CR) and a score of 5 was given to invasive adenocarcinoma or metastases. Prostates with areas of CR scattered among acini affected by adenocarcinoma were defined as being of partial regression 
Results
Tumor-directed vaccination is critical for therapeutic efficacy of hematopoietic cell transplantation against autochthonous prostate cancer in TRAMP mice. In our previous study we found that combining transplantation of HSCT and DLI from female mice pre-sensitized to male antigens and tumor-directed vaccination promoted long-term survival of tumor-prone TRAMP mice. Since donor sensitization against host antigens might be ethically questionable in clinical settings, we evaluated the therapeutic potential of HSCT/DLI from naïve, non-sensitized donors, mismatched to the recipient for defined sets of multiple minor H antigens, and the need for tumordirected post-transplant vaccination.
As donors of HSCT and DLI, we adopted congenic male B6 mice, allogeneic female cell responses, which we previously found to well correlate with cytotoxic T cell activity (17) in the spleen of TRAMP mice, transplanted as described in Figure 1A .
While IFN-γ + CD8 + Tag-IV-specific T cells readily accumulated in frequency ( Figure   3A and B) and total number ( Figure 3C 
IFN-γ competent T cells are required for tumor infiltration and regression.
Having found tumor-directed vaccination following HSCT and DLI to be critical for the priming, and potentially also for tumor-homing of IFN-γ-competent Tag It is worth mentioning that a higher fraction of TRAMP mice relapsed after transplants from non-sensitized donors (shown here) when compared to hostsensitized donors (17). We speculate that this might be attributed to the nature of the minor H antigen-specific T cell response, represented by naïve T cells in the current study and by memory T cells in the case of DLI from pre-sensitized donors.
Alloreactive memory T cells might simply outperform naïve T cells by being more resistant to clonal adaptation/exhaustion, which is frequently induced by ubiquitously expressed antigens (47). While we could not directly enumerate HY-specific T cells in the current manuscript, we did visualize TCR transgenic HY-specific naïve T cells in our previous study, and found these T cells able to expand in peripheral lymphoid organs and to infiltrate the tumor (17), but incapable to persist (unpublished data). In 
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